Variable expression of the uteroglobin gene following the administration of norethisterone and its A-ring reduced metabolites.
Enzyme-mediated A-ring reduction of norethisterone (NET) results in the transformation of a molecule with potent intrinsic progestational activity into neutral derivatives with estrogen-like effects. To ascertain whether these structural modifications of NET are able to modify the uteroglobin (U) gene (G) expression, a series of experiments assessing the UG products after the administration of NET and its reduced A-ring metabolites were conducted in prepubertal female rabbits. Synthesis of endometrial uteroglobin and its specific mRNA were studied in animals following the administration of NET, 5 alpha-dihydro NET,3 beta,5 alpha-tetrahydro NET and progesterone. Animals treated with either estradiol or vehicle alone served as controls. The uteroglobin content in uterine flushings and cytosols was determined by immunodiffusion and polyacrilamide gel electrophoresis techniques and by a specific double-antibody radioimmunoassay, while the U mRNA synthesis was assessed by its molecular hybridization to [alpha 32P]d-ATP uteroglobin cDNA. NET induced a significant increase of the uterine content of uteroglobin similar to that observed with progesterone with a simultaneous increase on U mRNA synthesis. On the contrary, 5 alpha-NET and 3 beta,5 alpha-NET induced very little, if any uteroglobin synthesis with a concomitantly low U mRNA production as compared with NET; thus exhibiting a similar effect to that observed in estradiol-treated animals. The overall results were interpreted as demonstrating that the enzyme mediated structural changes of NET which occur at the target organs induce variable expression of the uteroglobin gene. The data indicate that the rabbit uteroglobin gene products are suitable molecular markers to evaluate the hormonal potency of contraceptive synthetic progestins and their derivatives.
Cerbón
M A
MA
Department of Reproductive Biology, National Institute of Nutrition S. Zubirán, ENEP-Zaragoza, Mexico.
Pasapera
A M
AM
Gutiérrez-Sagal
R
R
García
G A
GA
Pérez-Palacios
G
G
D000818:Animals; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism; D005260:Female; D015870:Gene Expression; D005819:Genetic Markers; D006023:Glycoproteins / Q000235:genetics*; D009640:Norethindrone / Q000031:analogs & derivatives / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism*; D011817:Rabbits; D014598:Uteroglobin / Q000096:biosynthesis / Q000235:genetics*; D014599:Uterus / Q000187:drug effects / Q000378:metabolism*
D005819:Genetic Markers; D006023:Glycoproteins; D012333:RNA, Messenger; D014598:Uteroglobin; D009640:Norethindrone